

9 PUBLIKATIONSVERZEICHNIS

9.1 Originalarbeiten

Sutter AP, Höpfner M, **Huether A**, Maaser K, Scherübl H. (2005)

Targeting the epidermal growth factor receptor by erlotinib (TarcevaTM) for the treatment of esophageal cancer. *Int. J Cancer*, im Druck [Epub ahead of print]

Höpfner M, Baradari V, **Huether A**, Schöfl C, Scherübl H. (2005)

The insulin-like growth factor receptor 1 is a promising target for novel treatment approaches in neuroendocrine gastrointestinal tumors. *Endocr Relat Cancer*, im Druck [Epub ahead of print]

Huether A, Höpfner M, Baradari V, Schuppan D, Scherübl H. (2005)

EGFR blockade by cetuximab alone or as combination therapy for growth control of hepatocellular cancer. *Biochem Pharmacol*, 70(11):1568-78.

Sutter AP, Maaser K, Höpfner M, **Huether A**, Schuppan D, Scherübl H. (2005)

Cell cycle arrest and apoptosis induction in hepatocellular carcinoma cells by HMG-CoA reductase inhibitors. Synergistic antiproliferative action with ligands of the peripheral benzodiazepine receptor. *J Hepatol* 43(5):808-16

Huether A, Höpfner M, Sutter AP, Schuppan D, Scherübl H. (2005)

Erlotinib induces cell cycle arrest and apoptosis in hepatocellular cancer cells and enhances chemosensitivity towards cytostatics. *J Hepatol* 43(4):661-9

Höpfner M, Sutter AP, **Huether A**, Schuppan D, Zeitz M, Scherübl H. (2004)

Targeting the epidermal growth factor receptor by gefitinib for treatment of hepatocellular carcinoma. *J Hepatol* 41(6):1008-16

Höpfner M, Sutter AP, **Huether A**, Ahnert-Hilger G, Scherübl H. (2004)

A novel approach in the treatment of neuroendocrine gastrointestinal tumors: additive antiproliferative effects of interferon-gamma and meta-iodobenzylguanidine. *BMC Cancer* 21;4:23

9.2 Eingereicht zur Veröffentlichung

Huether A, Höpfner M, Sutter AP, Baradari V, Schuppan D, Scherübl H. (2005)

Signaling pathways modulated by epidermal growth factor receptor inhibition by erlotinib (TarcevaTM) in hepatocellular cancer cells. *Hepatology*

Höpfner M, **Huether A**, Sutter AP, Baradari V, Schuppan D, Scherübl H. (2005)

IGF-1 receptor tyrosine kinase inhibition has antineoplastic effects in hepatocellular carcinoma cells. *J Hepatol*

Höpfner M, Sutter AP, **Huether A**, Baradari V, Scherübl H. (2005)

The tyrosine kinase of the insulin-like growth factor receptor as target for novel treatment and prevention strategies of colorectal cancer. *Gut*

9.3 Vorträge

Huether A, Höpfner M, Sutter A, Brunk I, Ahnert-Hilger G, Scherübl H. (2004)

Unlabelled meta-Iodobenzylguanidine in the treatment of gastrointestinal neuroendocrine tumors. *Jahrestagung der Deutschen Pharmazeutischen Gesellschaft, Regensburg*

Huether A, Scherübl H. (2004)

Der Tyrosinkinaseinhibitor Erlotinib (TarcevaTM) in der Therapie des hepatozellulären Karzinoms (HCC), *Charité-CBF*

Huether A, Scherübl H. (2003)

Der Einsatz von meta-Iodobenzylguanidin in der Therapie neuroendokriner Tumoren des Gastrointestinaltraktes, *Charité-CBF*

9.4 Kurzveröffentlichungen und Posterabstracts

Huether A, Höpfner M, Sutter AP, Schuppan D, Scherübl H. (2005)

The EGFR-tyrosine kinase inhibitor erlotinib induces cell cycle arrest and apoptosis in hepatocellular cancer cells and enhances chemosensitivity towards cytostatics. *Jahrestagung der Deutschen Pharmazeutischen Gesellschaft, Mainz*

Huether A, Höpfner M, Schuppan D, Scherübl H. (2005)

Dual blockade of the epidermal growth factor receptor and the HMG-CoA-reductase for the treatment of hepatocellular cancer: additive antineoplastic effects of cetuximab, erlotinib and fluvastatin. *Hepatocellular carcinoma-EASL AASLD JSH Monothematic Conference Barcelona*

Baradari V, Höpfner M, **Huether A**, Scherübl H. (2005)

Specific inhibition of the IGFR tyrosine kinase as a novel approach for targeted therapy in neuroendocrine gastrointestinal tumor disease. *Z Gastroenterol* 43:P358

Höpfner M, **Huether A**; Baradari V, Schuppan D, Scherübl H. (2005)

The insulin-like growth factor receptor is a promising target for innovative treatment approaches of hepatocellular cancer. *Z Gastroenterol* 43:P357

Sutter AP, Höpfner M, **Huether A**, Maaser K, Scherübl H. (2005)

Targeting the epidermal growth factor receptor by erlotinib (TarcevaTM) for the treatment of esophageal cancer. *Z Gastroenterol* 43:P371

Huether A, Höpfner M, Schuppan D, Scherübl H. (2005)

Dual-agent molecular targeting of growth factors in hepatocellular cancer: Combining anti-EGFR antibody with an EGFR tyrosine kinase inhibitor. *Z Gastroenterol* 43:P369

Huether A, Höpfner M, Sutter AP, Grabowski P, Schuppan D, Zeitz M, Scherübl H. (2005)

The EGFR tyrosine kinase inhibitor erlotinib induces cell cycle arrest and apoptosis in human hepatocellular cancer cells and enhances chemosensitivity to doxorubicin, docetaxel, and SN-38. *J Hepatol* 42, supplement 2:P346

Huether A, Höpfner M, Sutter AP, Schuppan D, Zeitz M, Scherübl H. (2005)

Targeting the epidermal growth factor receptor by erlotinib (Tarceva™) for the treatment of hepatocellular cancer. *Gastroenterology* 128(4), Supplement 2

Sutter AP, Maaser K, Grabowski P, **Huether A**, Bradacs G, Vormbrock K, Höpfner M, Krahn A, Heine B, Stein H, Somasundaram R, Schuppan D, Zeitz M, Scherübl H. (2004)

Peripheral benzodiazepine receptor ligands enhance chemosensitivity of hepatocellular carcinoma cells. *Jahrestagung der Deutschen Pharmazeutischen Gesellschaft, Regensburg*

Höpfner M, Sutter AP, **Huether A**, Gerst B, Zeitz M, Scherübl H. (2004)

Antitumor activity of the selective epidermal growth factor receptor-tyrosine kinase inhibitor gefitinib (ZD1839) in neuroendocrine gastrointestinal tumor cells. *Gastroenterology* 126, Supplement 2

Fliss G, **Huether A**, Eickhoff C, Heidecke H, Kloft C. (2002)

First successful step in the development of a determination system to predict the effect time course in tumor therapy. *Arch. Pharm. Pharm Med Chem* Supplement1, P:K2